Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug trial hopes to ease muscle stiffness in rare disease

NCT ID NCT07486934

First seen Apr 02, 2026 · Last updated May 20, 2026 · Updated 9 times

Summary

This study tests a new medicine, DYNE-101, for adults with myotonic dystrophy type 1, a condition that causes muscle weakness and stiffness. About 150 people will receive either the drug or a placebo for 48 weeks. The goal is to see if the drug improves muscle function, like standing up from a chair and opening hands faster.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DM1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Hospital Organization Osaka Toneyama Medical Center

    RECRUITING

    Toyonaka-Shi, Osaka, 560-8552, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Rare Disease Research, LLC

    RECRUITING

    Atlanta, Georgia, 30329, United States

    Contact Email: •••••@•••••

  • Rare Disease Research, LLC

    RECRUITING

    Hillsborough, North Carolina, 27278, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The University of Texas Health Science Center at San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Yamaguchi University Hospital

    RECRUITING

    Ube-Shi, Yamaguchi, 755-8505, Japan

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.